MBX
MBX Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.48
+5.79%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.83
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.78
- EPS estimate
- -$0.63
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +7.6%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $103
- PT range
- $84 – $150
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.63 | -$0.78 | Miss -23.32% | — |
| May 14, 2026 | -$0.62 | -$0.51 | Beat 17.74% | — |
| Mar 12, 2026 | -$0.63 | -$0.49 | Beat 22.17% | — |
| Nov 6, 2025 | -$0.73 | -$0.63 | Beat 13.70% | — |
| Aug 7, 2025 | -$0.77 | -$0.58 | Beat 24.68% | — |
| Mar 17, 2025 | -$0.59 | -$0.47 | Beat 20.34% | — |
| Nov 7, 2024 | -$2.72 | -$2.78 | Miss -2.21% | — |
| Dec 31, 2023 | — | -$0.26 | — | — |
| Sep 30, 2023 | — | -$0.32 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026